If President Trump follows through on a threat to halt Obamacare’s “cost-sharing reduction” program, New York has more to lose than almost any other state.
Opioid prescribing rates vary widely across New York, with residents in some counties receiving three or four times as much of the potentially addictive pain relievers as in other counties.
Insurance tax credits in the U.S. Senate GOP’s health plan would have a mixed effect on New Yorkers, reducing net premiums for some young, low-income consumers shopping in the non-group market, but raising costs for older ones.
The U.S. Senate GOP’s health bill, though pitched as more moderate than the House plan, would be harder on New York in at least one respect.
The makers of the anti-addiction drug Vivitrol – whose controversial nationwide lobbying campaign was spotlighted by the New York Times last week – appear to be getting results in Albany.
State legislators have taken their mania for insurance mandates to a new extreme: They’ve passed a bill that arguably accomplishes nothing other than covering unnecessary mammograms.
The double-digit premium hikes looming for non-group health insurance consumers in New York appear to be driven more by state and federal government policy than by the underlying cost of medical care.
As health plans across the state announce their requested premium increases for 2018, the Cuomo administration’s policy decisions are taking more blame than the turmoil in Washington.
There are plenty of reasons for New Yorkers to be leery of the House Republican health plan, but Governor Andrew Cuomo’s gestures of resistance on Monday raise several objections
Thanks to New York’s unusual insurance laws, the impact of the House GOP health plan on the state’s non-group insurance market would be dramatically different than than virtually anywhere else.
The House GOP is a model of cautious deliberation next to the Assembly’s handling of the New York Health Act, which would establish a statewide single-payer plan.